Protara Therapeutics, Inc. — Form 10-Q

Protara amended its certificate of incorporation (effective June 12, 2026) to add Article Thirteen providing officer exculpation from fiduciary duty liability (similar to director protections in Article Ten, with carve-outs for disloyalty, bad faith, intentional misconduct, and improper benefit). Separately, the 2024 Equity Incentive Plan was amended (effective April 8, 2026, subject to stockholder approval) to increase authorized shares under the plan from an unspecified prior amount to 9,300,000 shares, including a cap on incentive options at 9,300,000 shares.